Identification of selective inhibitors of Plasmodium N-myristoyltransferase by high-throughput screening.

New drugs that target Plasmodium species, the causative agents of malaria, are needed. The enzyme N-myristoyltransferase (NMT) is an essential protein which catalyzes the myristoylation of protein substrates, often to mediate membrane targeting. We screened ~1.8 million small molecules for activity against Plasmodium vivax NMT. Hits were triaged based on potency and physicochemical properties and further tested against P. vivax and P. falciparum NMTs. We assessed the activity of hits against human NMT1 and NMT2 and discarded compounds with low selectivity indices. We identified 23 chemical classes specific for the inhibition of Plasmodium NMTs over human NMTs, including multiple novel scaffolds. Co-crystallization of P. vivax NMT with one compound revealed peptide binding pocket binding. Other compounds show a range of potential modes of action. Our data provide insight into the activity of a collection of selective inhibitors of Plasmodium NMT and serve a starting point for subsequent medicinal chemistry efforts.

[1]  Edward W. Tate,et al.  Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors , 2019, Cell chemical biology.

[2]  S. Norval,et al.  A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors , 2018, Journal of medicinal chemistry.

[3]  S. Johnston,et al.  Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus , 2018, Nature Chemistry.

[4]  A. Holder,et al.  N-Myristoylation as a Drug Target in Malaria: Exploring the Role of N-Myristoyltransferase Substrates in the Inhibitor Mode of Action. , 2018, ACS infectious diseases.

[5]  K. Paaijmans,et al.  malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication , 2017, PLoS medicine.

[6]  D. Fidock,et al.  Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic , 2017, Nature Medicine.

[7]  J. Burrows,et al.  New developments in anti-malarial target candidate and product profiles , 2017, Malaria Journal.

[8]  A. Fairlamb,et al.  The N-myristoylome of Trypanosoma cruzi , 2016, Scientific Reports.

[9]  S. Agnandji,et al.  Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials. , 2015, Future microbiology.

[10]  Edward W. Tate,et al.  Global Analysis of Protein N-Myristoylation and Exploration of N-Myristoyltransferase as a Drug Target in the Neglected Human Pathogen Leishmania donovani , 2015, Chemistry & biology.

[11]  Edward W. Tate,et al.  Structure-Based Design of Potent and Selective LeishmaniaN-Myristoyltransferase Inhibitors , 2014, Journal of medicinal chemistry.

[12]  Edward W. Tate,et al.  Design and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N-Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP) , 2014, Journal of medicinal chemistry.

[13]  Edward W. Tate,et al.  Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach. , 2014, Nature chemistry.

[14]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[15]  David M. Wilson,et al.  A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery , 2013, PloS one.

[16]  Pannamas Maneekan,et al.  Border Malaria Associated with Multidrug Resistance on Thailand-Myanmar and Thailand-Cambodia Borders: Transmission Dynamic, Vulnerability, and Surveillance , 2013, BioMed research international.

[17]  F. Nosten,et al.  Malaria Burden and Artemisinin Resistance in the Mobile and Migrant Population on the Thai–Myanmar Border, 1999–2011: An Observational Study , 2013, PLoS medicine.

[18]  M. Llinás,et al.  A Tetracycline-Repressible Transactivator System to Study Essential Genes in Malaria Parasites , 2012, Cell host & microbe.

[19]  A. Holder,et al.  Design and synthesis of inhibitors of Plasmodium falciparum N-myristoyltransferase, a promising target for antimalarial drug discovery. , 2012, Journal of medicinal chemistry.

[20]  Edward W. Tate,et al.  Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs , 2012, PLoS neglected tropical diseases.

[21]  Qiang Fang,et al.  Malaria in the Greater Mekong Subregion: heterogeneity and complexity. , 2012, Acta tropica.

[22]  Emmanuelle Thinon,et al.  A fluorescence-based assay for N-myristoyltransferase activity. , 2012, Analytical biochemistry.

[23]  Yongyuth Yuthavong,et al.  A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.

[24]  A. Hill,et al.  Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. , 2010, Drug discovery today.

[25]  James R. Brown,et al.  Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.

[26]  Andrew R. Leach,et al.  An Introduction to Chemoinformatics , 2003 .

[27]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[28]  Sebastian Maurer-Stroh,et al.  N-terminal N-myristoylation of proteins: refinement of the sequence motif and its taxon-specific differences. , 2002, Journal of molecular biology.

[29]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[30]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[31]  Isabel Coma,et al.  Statistics and decision making in high-throughput screening. , 2009, Methods in molecular biology.